RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Marketable securities, current

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$109.6B
P/E ratio
SummaryFinancials
Period EndMarketable securities, current (Million USD)YoY (%)
Dec 31, 20241,546+82.09%
Dec 31, 2023849+209.36%
Dec 31, 2022275-62.39%
Dec 31, 2021730+8.83%
Dec 31, 2020671-4.04%
Dec 31, 2019699-32.55%
Dec 31, 20181,036+22.41%
Dec 31, 2017847+237.78%
Dec 31, 2016251-23.52%
Dec 31, 2015328-56.99%
Dec 31, 2014762-14.95%
Dec 31, 2013896+7.69%
Dec 31, 2012832+68.52%
Dec 31, 2011494-37.38%
Dec 31, 2010788

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)